Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 22, 2026

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Drug Screening of Sarcoma Cells: Finding Shared Sensitivities.

Hannah C Beird1, Carl Ho1, Roberto Cardenas-Zuniga2

  • 1Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Cancer Research Communications
|May 21, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

Leukemia·2026
Same author

Pooled Analysis of Trabectedin Efficacy in Myxoid/Round Cell Liposarcoma from Three Prospective Clinical Trials.

Cancers·2026
Same author

Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.

Nature communications·2026
Same author

LPAR4 mediates resistance to interferon-induced stress in soft tissue sarcoma.

Science advances·2026
Same author

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.

Cancer research communications·2026
Same author

Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States.

bioRxiv : the preprint server for biology·2026

This study screened 1387 compounds to find drugs for chemoresistant sarcomas. Microtubule inhibitors and aurora kinase inhibitors showed promise, with specific drugs effective against Ewing sarcoma and other subtypes.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Over 130 World Health Organization (WHO)-defined sarcoma subtypes exist.
  • Many sarcoma subtypes exhibit chemoresistance, presenting a significant unmet clinical need.
  • Identifying novel therapeutic strategies and drug repurposing opportunities is crucial for improving sarcoma patient outcomes.

Purpose of the Study:

  • To screen a diverse collection of small molecules for potential repurposing in sarcoma treatment.
  • To identify effective drug candidates against various sarcoma histologies.
  • To explore differential drug sensitivity across sarcoma subtypes and identify potential therapeutic vulnerabilities.

Main Methods:

  • A library of 1387 structurally diverse small molecules was screened.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Experiment Videos

Last Updated: May 22, 2026

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

  • Screening was performed across 20 sarcoma cell lines representing various histologies.
  • Differential drug sensitivity was analyzed based on sarcoma subtype.

    • Main Results:

    • Microtubule inhibitors, aurora kinase inhibitors, and heat shock protein inhibitors were identified as the most effective agents.
    • Ewing sarcoma showed sensitivity to aurora kinases and the mTOR inhibitor TORIN-2.
    • Myxoid liposarcoma and synovial sarcomas were sensitive to SNS-032, a CDK2/7/9 inhibitor that abrogates the YAP pathway.

    Conclusions:

    • Drug repurposing screens can identify effective agents for chemoresistant sarcomas.
    • Sarcoma subtypes exhibit differential drug sensitivities, suggesting unique molecular vulnerabilities.
    • Targeting shared driver pathways, such as YAP, may offer therapeutic opportunities across different sarcoma histologies.